IP Library Granted Patent US 12,076,366
Granted Patent B2
US 12,076,366 · App. 16/920,652 · Granted Sep 3, 2024

Therapeutic vitamin D conjugates

Inventors: Tarik Soliman (Cambridge, MA); Laura M. Hales (Cambridge, MA); Daniel B. Hall (Easton, MA); Christopher So (Henderson, NV); Howard P. Sard (Arlington, MA); Vishnumurthy Hegde (Chelmsford, MA)
Assignee: Extend Biosciences, Inc.
A61K38/10A61K9/0019A61K38/22A61K47/551A61K47/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,076,366
App. No.
16/920,652
Granted
Sep 3, 2024
Kind
B2
Abstract

The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.

Claims (10)

1. A method of treating osteoporosis or hypoparathyroidism in a patient in need thereof, comprising administering an effective amount of a pharmaceutical composition comprising a carrier-drug conjugate comprising a targeting group that is a vitamin D that is not hydroxylated at the carbon 1 position conjugated via a scaffold to a therapeutic peptide at the carbon 3 position of said vitamin D targeting group, wherein said targeting group interacts with the vitamin D binding protein (DBP) to increase the absorption, bioavailability, or half-life of said therapeutic peptide in circulation when compared to a form of said therapeutic peptide conjugated to said vitamin D targeting group at the carbon 25 position; wherein said therapeutic peptide has PTH activity and comprises an amino acid sequence with at least a 90% sequence identity to either SEQ ID NO:10 or SEO ID NO:17.

2. The method of claim 1 , wherein said pharmaceutical composition is administered to said patient by a transdermal, oral, parenteral, subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional, intracranial injection, infusion, inhalation, ocular, topical, rectal, nasal, buccal, sublingual, vaginal, or implanted reservoir mode.

3. The method of claim 1 , wherein said scaffold is poly(ethylene glycol).

4. The method of claim 1 , wherein said peptide has the sequence of SEQ ID NO:10.

5. The method of claim 4 , wherein said scaffold is poly(ethylene glycol).

6. The method of claim 1 , wherein said therapeutic peptide has the sequence of SEQ ID NO:17.

7. The method of claim 6 , wherein said scaffold is poly(ethylene glycol).

8. The method of claim 1 , wherein said scaffold is poly(propyleneglycol).

9. The method of claim 4 , wherein said scaffold is poly(propyleneglycol).

10. The method of claim 6 , wherein said scaffold is poly(propyleneglycol).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: SOLIMAN, TARIK; HALES, LAURA M.; HALL, DANIEL B.; SO, CHRISTOPHER
To: EXTEND BIOSCIENCES, INC.
Reel/Frame 053561/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: SARD, HOWARD P.; HEGDE, VISHNUMURTHY
To: ORGANIX, INC.
Reel/Frame 053561/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: ORGANIX, INC.
To: EXTEND BIOSCIENCES, INC.
Reel/Frame 053561/0698 →
Continuity (5)
Division 15430449 · Feb 11, 2017
Continuation 14919601 · Oct 21, 2015
Provisional Application 62244181 · Oct 20, 2015
Provisional Application 62067388 · Oct 22, 2014
Related Publication 20210008153A1 · Jan 14, 2021